Wednesday , 27 November 2024
Home Health Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition
Health

Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition

Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition

Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications. The two companies have been partners in hematological malignancies since 2022.

The post Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition appeared first on MedCity News.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

What to Know Ahead of the Supreme Court Case on Youth Access to Gender Affirming Care

This brief provides background on gender affirming care and state bans, explains...

Your Guide To Affordable and Effective Spine Surgery Treatment in India

619 million people across the globe have reported issues of chronic back...

Stick to the Science

By KIM BELLARD A year ago I wrote about disturbing news from...

How Integrated Delivery Systems Are Transforming Healthcare

How are Integrated Delivery Networks (IDNs) shaping the future of healthcare, and...